(1 - 13 von 24
)
Santhera im Geschäftsjahr mit Einnahmen von CHF 20,6 Mil ...
www.mittelstandcafe.de
Klaus Schollmeier, Chief Executive Officer von Santhera. «Ein weiterer wichtiger. Höhepunkt des vergangenen Jahres war die Auslizenzierung von Fipamezole an Ipsen für Regionen ausserhalb Nordamerikas und Japans. ...
Biovail to acquire Santhera's US & Canadian rights of JP
test.pharmabiz.com
... will become a key product for the improved management of Parkinson's disease," said Klaus Schollmeier, chief executive officer of Santhera." › news
Baxter Acquires SuppreMol - Contract Pharma
www.contractpharma.com
— ... goal to treat important autoimmune diseases and severe allergies,” said Klaus Schollmeier, Ph.D., chief executive officer of SuppreMol. › ...
Biovail to Acquire Rights to Develop, Commercialize JP
ir.bauschhealth.com
— ... become a key product for the improved management of Parkinson's disease,” said Klaus Schollmeier, Chief Executive Officer of Santhera.”. › archive
sortiert nach Relevanz / Datum